ENSURE-AF Trial Supports Edoxaban for Electrical Cardioversion
ROME — Results of the largest-ever randomized clinical trial of anticoagulation for electrical cardioversion of patients with nonvalvular atrial fibrillation demonstrate that edoxaban is a safe, effective, and convenient alternative to the standard strategy of enoxaparin as a bridge to warfarin.
Source: Caring for the Ages - Category: Health Management Authors: Bruce Jancin Source Type: news
More News: Atrial Fibrillation | Cardiology | Clinical Trials | Coumadin | Heart | Lovenox | Warfarin